{"id":62332,"date":"2025-12-22T18:42:02","date_gmt":"2025-12-22T13:12:02","guid":{"rendered":"https:\/\/www.nextias.com\/ca\/?p=62332"},"modified":"2025-12-23T17:22:18","modified_gmt":"2025-12-23T11:52:18","slug":"data-exclusivity-in-india","status":"publish","type":"post","link":"https:\/\/www.nextias.com\/ca\/current-affairs\/22-12-2025\/data-exclusivity-in-india","title":{"rendered":"Data Exclusivity in India"},"content":{"rendered":"\n<p><strong>Syllabus: GS3\/Science and Technology<\/strong><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Context<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>The Indian government is considering implementing <strong>\u201cdata exclusivity\u201d in the pharmaceutical drugs sector.<\/strong><\/li>\n\n\n\n<li>The government\u2019s approach appears to be driven by the expectation that the provision could help bring in additional investment in the country.\u00a0<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Patent in Pharmaceutical Industry<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>In the pharmaceutical industry, patents are broadly classified based on <strong>what aspect of a drug or process is being protected.<\/strong>\n<ul class=\"wp-block-list\">\n<li><strong>Pharma patents protect<\/strong> drug molecules, processes, formulations, uses, and delivery systems.<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Types of Patents in India are: <\/strong>Product Patent, Process Patent, Improvement Patent and Biotechnology Patent.<\/li>\n\n\n\n<li><strong>Criteria: <\/strong>An invention must satisfy:\n<ul class=\"wp-block-list\">\n<li>Novelty i.e. it is new worldwide.<\/li>\n\n\n\n<li><strong>Inventive Step: <\/strong>An invention must not be an obvious modification or simple combination of existing knowledge.<\/li>\n\n\n\n<li><strong>Industrial Applicability:<\/strong> It is capable of being made or used in industry.<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Term of Patent: 20 years<\/strong> from date of filing which is compliant to <strong>TRIPS<\/strong>.<\/li>\n\n\n\n<li><strong>Compulsory Licensing (CL): <\/strong>Compulsory licensing is when a government allows someone else to produce a patented product or process <strong>without the consent of the patent owner<\/strong>. It is allowed under <strong>Section 84 of Patents Act, 1970<\/strong> when:\n<ul class=\"wp-block-list\">\n<li>Reasonable public requirements not met.<\/li>\n\n\n\n<li>Drugs are not affordable.<\/li>\n\n\n\n<li>The patented invention isn&#8217;t worked (manufactured\/exploited) in India.<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li>There is an international filing system known as <strong>Patent Cooperation Treaty (PCT) system.<\/strong>\n<ul class=\"wp-block-list\">\n<li>When a PCT application is filed, an inventor of a member country of PCT can simultaneously obtain priority for his\/her invention in all the PCT member countries.\u00a0<\/li>\n\n\n\n<li><strong>India joined PCT in 1998.\u00a0<\/strong><\/li>\n\n\n\n<li>All activities related to PCT are coordinated by the <strong>World Intellectual Property Organization (WIPO) situated in Geneva.\u00a0<\/strong><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-background has-fixed-layout\" style=\"background-color:#ebecf0\"><tbody><tr><td><strong>Trade-Related Aspects of Intellectual Property Rights (TRIPS)<\/strong><br><br>&#8211; TRIPS is a <strong>binding <\/strong>WTO agreement that sets <strong>minimum global standards<\/strong> for the protection and enforcement of Intellectual Property Rights (IPRs).<br>&#8211; It has been in force since <strong>1995.<\/strong><br>&#8211; It is binding on all WTO members, including India.<br><br><strong>World Intellectual Property Organization (WIPO)<\/strong>\u00a0<br>&#8211; It is a <strong>self-funding agency of the United Nations, <\/strong>that serves the world\u2019s innovators and creators, ensuring that their ideas travel safely to the market and improve lives everywhere.<br>&#8211; <strong>History:<\/strong> WIPO was established in <strong>1967<\/strong> by the<strong> WIPO Convention.<\/strong>\u00a0<br>&#8211; <strong>Members:<\/strong> The organization has <strong>194<\/strong> member states including both developing and developed nations like India, Italy, Israel, Austria, Bhutan, Brazil, China, Cuba, Egypt, Pakistan, the U.S. and the U.K.<br>a. India joined WIPO in <strong>1975.\u00a0<\/strong><br>&#8211; <strong>Headquarters:<\/strong> Geneva, Switzerland.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Data Exclusivity<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>In the Absence of Data Exclusivity:<\/strong> When a company develops a new drug, it must <strong>submit clinical trial data<\/strong> demonstrating the safety and efficacy of its product<strong> to regulators.\u00a0<\/strong>\n<ul class=\"wp-block-list\">\n<li>The regulator may use this data to approve<strong> another company\u2019s generic version<\/strong> on the basis of much less resource-intensive bio-equivalence studies.<\/li>\n\n\n\n<li><strong>The generic manufacturer <\/strong>can then start marketing its <strong>generic drugs on the date the original company\u2019s patent ends.<\/strong><\/li>\n\n\n\n<li>Data exclusivity is not implemented in India&#8217;s regulatory system <strong>to prioritize affordable medicine access over originator data protection.\u00a0<\/strong>\n<ul class=\"wp-block-list\">\n<li>India&#8217;s approach has enabled the country to develop the <strong>world&#8217;s largest generic pharmaceutical sector<\/strong>.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Data Exclusivity: <\/strong>This provision grants <strong>innovator pharmaceutical companies exclusive rights <\/strong>over the <strong>clinical trial data<\/strong>, meaning a regulator cannot use it to grant approvals to generic versions.\n<ul class=\"wp-block-list\">\n<li>So, generic drug companies have to either wait until the exclusivity expires or carry out expensive clinical trials themselves to prove safety and efficacy.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Significance of Data Exclusivity<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Incentive for Innovation:<\/strong> Data exclusivity in India can protect the<strong> <\/strong>costly and risky clinical trial investments which eventually encourages new drug discovery and R&amp;D.<\/li>\n\n\n\n<li><strong>Attracts Foreign Investment:<\/strong> By providing<strong> <\/strong>predictable regulatory protection, India might be seen as an IP-secure destination and will attract a large amount of\u00a0 FDI in the Pharma sector.<\/li>\n\n\n\n<li><strong>Boost to Original Research: <\/strong>It encourages Indian firms to move from reverse engineering to innovative drug development.<\/li>\n\n\n\n<li><strong>Alignment with Global Practices: <\/strong>Countries and groupings like USA, EU, Japan provide data exclusivity, India can also become a part of the nations protecting rights of the original innovator.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Concerns with Data Exclusivity&nbsp;<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Delay in Generic Drug Entry: <\/strong>It will block approval of generics creating a de facto monopoly beyond patent term.<\/li>\n\n\n\n<li><strong>Harms Domestic Generic Industry:<\/strong> If India were to agree to data exclusivity provisions, its generics-focused pharmaceutical industry may lose its edge in international markets.\n<ul class=\"wp-block-list\">\n<li>Almost 90% of Indian pharmaceutical companies manufacture generic drugs, they do not invest in developing new ones.<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Increases Cost of Medicines:<\/strong> This will also delay access to cheaper medicines to the people of the country.<\/li>\n\n\n\n<li><strong>Ethical Issues in Clinical Trials:<\/strong> It can lead to Pharma companies conducting questionable, unnecessary clinical trials to get incentives.<\/li>\n\n\n\n<li><strong>Impact on Healthcare System: <\/strong>It will lead to the lower availability of affordable medicines which will increase burden on public health systems in India.<\/li>\n\n\n\n<li><strong>Impact on Global Health:<\/strong> India is the pharmacy of the world, exporting cheap generic drugs all over the world. Data Exclusivity will impact the supply of affordable drugs to Africa, Asia, Latin America.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Way Ahead<\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>While data exclusivity can incentivise innovation and investment, in India it risks delaying generic competition, raising drug prices, and undermining public health.\u00a0<\/li>\n\n\n\n<li>India\u2019s cautious rejection of data exclusivity reflects a conscious choice to prioritise affordable access to medicines while using TRIPS flexibilities wisely.<\/li>\n<\/ul>\n\n\n\n<p><strong>Source: <\/strong><a href=\"https:\/\/indianexpress.com\/article\/explained\/what-is-data-exclusivity-in-drugs-10431588\/\" target=\"_blank\" rel=\"noopener\"><strong>IE<\/strong><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p><strong>Context<\/strong><\/p>\n<li class=\"ms-5\">The Indian government is considering implementing \u201cdata exclusivity\u201d in the pharmaceutical drugs sector.<\/li>\n<li class=\"ms-5\">The government\u2019s approach appears to be driven by the expectation that the provision could help bring in additional investment in the country.\u00a0<\/li>\n<p><\/p>\n<p><strong>Patent in Pharmaceutical Industry<\/strong><\/p>\n<li class=\"ms-5\">In the pharmaceutical industry, patents are broadly classified based on what aspect of a drug or process is being protected.<\/li>\n<li class=\"ms-5\">Pharma patents protect drug molecules, processes, formulations, uses, and delivery systems.<\/li>\n<li class=\"ms-5\">Types of Patents in India are: Product Patent, Process Patent, Improvement Patent and Biotechnology Patent.<\/li>\n<p><a href=\"https:\/\/www.nextias.com\/ca\/current-affairs\/22-12-2025\/data-exclusivity-in-india\" class=\"btn btn-primary btn-sm float-end\">Read\u00a0More<\/a><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[21],"tags":[],"class_list":["post-62332","post","type-post","status-publish","format-standard","hentry","category-current-affairs"],"acf":[],"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/www.nextias.com\/ca\/wp-json\/wp\/v2\/posts\/62332","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.nextias.com\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.nextias.com\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.nextias.com\/ca\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nextias.com\/ca\/wp-json\/wp\/v2\/comments?post=62332"}],"version-history":[{"count":2,"href":"https:\/\/www.nextias.com\/ca\/wp-json\/wp\/v2\/posts\/62332\/revisions"}],"predecessor-version":[{"id":62334,"href":"https:\/\/www.nextias.com\/ca\/wp-json\/wp\/v2\/posts\/62332\/revisions\/62334"}],"wp:attachment":[{"href":"https:\/\/www.nextias.com\/ca\/wp-json\/wp\/v2\/media?parent=62332"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.nextias.com\/ca\/wp-json\/wp\/v2\/categories?post=62332"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.nextias.com\/ca\/wp-json\/wp\/v2\/tags?post=62332"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}